Melanoma — IVAO

Study for the Evaluation of Vemurafenib ( Zelboraf® ) and Ipilimumab ( Yervoy® ) in Combination With DNE3 Therapy to Patients With Metastatic Melanoma

Прекращено

Терапия: Vemurafenib 960 mg tablet by mouth (oral) twice daily; Ipilimumab 10 mg/kg Intravenous (IV) injection; DNE3 0.2 g/kg of body weight